BRITE-338733
Based on 1 Customer Validation
BRITE-338733 is an inhibitor of E. coli RecA ATPase activity (IC50: 4.7 μM). BRITE-338733 also inhibits the ATP hydrolysis activity of RSC chromatin remodeling enzyme by binding to its ATP-binding pocket and DNA (IC50: 0.316 μM). BRITE-338733 exhibits cytotoxicity against MCF-7 and MDA-MB-231 breast cancer cells. BRITE-338733 can be used in studies on antibacterial adjuvants and anticancer research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.93%
- No. CAS: 503105-88-2
- Fòrmula: C27H35N3O2
- Peso molecular:433.59
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
IC50: 4.7 µM (RecA ATPase)[1]
BRITE-338733 exhibits strong and stable binding affinity for the ATPase domain of Sth1, the catalytic subunit of the yeast RSC complex[2].
BRITE-338733 (0.5-1 mM; 20 min) potently inhibits the ATP hydrolysis activity of purified yeast RSC complex, with an IC50 of 0.316 μM[2].
BRITE-338733 (0.1-100 μM; 6-24 h) exhibits cytotoxicity against the human breast cancer cell lines MCF-7 and MDA-MB-231[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 human breast cancer cell line, MDA-MB-231 human breast cancer cell line
-
Concentration:0.1, 1, 10, 100 μM
-
Incubation Time:6 h, 24 h
-
Result:Had an IC50 of 7.852 μM in MCF-7 cells and 6.579 μM in MDA-MB-231 cells after 6 h of treatment.
Had an IC50 of 5.098 μM in MCF-7 cells and 3.960 μM in MDA-MB-231 cells after 24 h of treatment.
Caused over 95% cytotoxicity at concentrations above 12.5 μM.
Chemical Information
-
No. CAS 503105-88-2
-
Appearance Solid
-
Peso molecular 433.59
-
Fòrmula C27H35N3O2
-
Color Off-white to light yellow
-
SMILES
OC1=CC=C(C)C=C1C2=NC(NC3CC(C)(C)NC(C)(C)C3)=CC(C4=CC=C(CC)O4)=C2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
1 M HCl : 100 mg/mL (230.63 mM; Need ultrasonic)
DMSO : 10 mg/mL (23.06 mM; ultrasonic and adjust pH to 4 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.31 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (2.31 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 1 M HCl | 1 mM | 2.3063 mL | 11.5316 mL | 23.0633 mL | 57.6582 mL |
| 5 mM | 0.4613 mL | 2.3063 mL | 4.6127 mL | 11.5316 mL | |
| 10 mM | 0.2306 mL | 1.1532 mL | 2.3063 mL | 5.7658 mL | |
| 15 mM | 0.1538 mL | 0.7688 mL | 1.5376 mL | 3.8439 mL | |
| 20 mM | 0.1153 mL | 0.5766 mL | 1.1532 mL | 2.8829 mL | |
| 1 M HCl | 25 mM | 0.0923 mL | 0.4613 mL | 0.9225 mL | 2.3063 mL |
| 30 mM | 0.0769 mL | 0.3844 mL | 0.7688 mL | 1.9219 mL | |
| 40 mM | 0.0577 mL | 0.2883 mL | 0.5766 mL | 1.4415 mL | |
| 50 mM | 0.0461 mL | 0.2306 mL | 0.4613 mL | 1.1532 mL | |
| 60 mM | 0.0384 mL | 0.1922 mL | 0.3844 mL | 0.9610 mL | |
| 80 mM | 0.0288 mL | 0.1441 mL | 0.2883 mL | 0.7207 mL | |
| 100 mM | 0.0231 mL | 0.1153 mL | 0.2306 mL | 0.5766 mL |
BRITE-338733 Related Classifications
HY-112589 Related Classifications
Powered by Bioz